ArticleInfection and immunity1995
Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein.
Article in Infection and immunity, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
189 citing papers in PubMed, 572 citations in OpenAlex.
- Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial.Critical care medicine · 2015Trial
- Vitamin D(3) induces expression of human cathelicidin antimicrobial peptide 18 in newborns.International journal of hematology · 2009Trial
- Antimicrobial proteins regulating neuroinflammation.Annals of medicine · 2026Review
- One-Step Design of Potent and Nonhemolytic Antimicrobial Peptides by Using a Database-Guided, Nonmachine Learning Approach.ACS infectious diseases · 2026Article
- Immunomodulatory Effects of the Antimicrobial Peptide KR-20: Implications for Trichomoniasis.Molecules (Basel, Switzerland) · 2026Article
- Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a CaBiochemistry and biophysics reports · 2025Article
- Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Unveiling mechanisms of antimicrobial peptide: Actions beyond the membranes disruption.Heliyon · 2024Review
- Host defense peptides human β defensin 2 and LL-37 ameliorate murine necrotizing enterocolitis.iScience · 2024Article
- Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids.Biophysical journal · 2024Review
- LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases.Biomolecules · 2024Review
- Enhancement of innate immunity in gingival epithelial cells by vitamin D and HDAC inhibitors.Frontiers in oral health · 2024Article
- A Simple Synthesis and Microstructure Analysis of Human Peptide LL-37@Gold Nanoparticles (Known as LL-37@AuNPs) Conjugates as Antimicrobials and Substances for Wound Healing.Materials (Basel, Switzerland) · 2023Article
- Antimicrobial Peptides Targeting Streptococcus mutans: Current Research on Design, Screening and Efficacy.Current microbiology · 2023Review
- Heterogeneity of Lipopolysaccharide as Source of Variability in Bioassays and LPS-Binding Proteins as Remedy.International journal of molecular sciences · 2023Review
- Role of antimicrobial peptide cathelicidin in thrombosis and thromboinflammation.Frontiers in immunology · 2023Review
- Antimicrobial peptides: natural or synthetic defense peptides against HBV and HCV infections.Virusdisease · 2022Review
- Important Roles and Potential Uses of Natural and Synthetic Antimicrobial Peptides (AMPs) in Oral Diseases: Cavity, Periodontal Disease, and Thrush.Journal of functional biomaterials · 2022Review
- Regulation of LL-37 in Bone and Periodontium Regeneration.Life (Basel, Switzerland) · 2022Review
- Alternative Antibiotics in Dentistry: Antimicrobial Peptides.Pharmaceutics · 2022Review
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
CAP18 (18-kDa cationic antimicrobial protein) is a protein originally identified and purified from rabbit leukocytes on the basis of its capacity to bind and inhibit various activities of lipopolysaccharide (LPS). Here we report the cloning of human CAP18 and characterize the anti-LPS activity of the C-terminal fragment. Oligonucleotide probes designed from the rabbit CAP18 cDNA were used to identify human CAP18 from a bone marrow cDNA library. The cDNA encodes a protein composed of a 30-amino-acid signal peptide, a 103-amino-acid N-terminal domain of unknown function, and a C-terminal domain of 37 amino acids homologous to the LPS-binding antimicrobial domain of rabbit CAP18, designated CAP18(104-140). A human CAP18-specific antiserum was generated by using CAP18 expressed as a fusion protein with the maltose-binding protein. Western blots (immunoblots) with this antiserum showed specific expression of human CAP18 in granulocytes. Synthetic human CAP18(104-140) and a more active truncated fragment, CAP18(104-135), were shown to (i) bind to erythrocytes coated with diverse strains of LPS, (ii) inhibit LPS-induced release of nitric oxide from macrophages, (iii) inhibit LPS-induced generation of tissue factor, and (iv) protect mice from LPS lethality. CAP18(104-140) may have therapeutic utility for conditions associated with elevated concentrations of LPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.